UP!
Clovis Oncology is a mid-sized pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline.
Its products include:
The company was developing rociletinib, as a treatment for non-small cell lung cancer. A phase III trial was completed in April 2016 and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib). According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.
Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.
Lucitanib is a VEGFR inhibitor. it is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-01 | Future report Set alerts | |
| Q2 2022 | 2022-08-08 | -0.50 | -0.50 |
| Q1 2022 | 2022-05-04 | -0.44 | -0.44 |
| Q4 2021 | 2022-02-23 | -0.48 | -0.48 |
| Q3 2021 | 2021-11-03 | -0.56 | -0.56 |
| Q2 2021 | 2021-08-04 | -0.61 | -0.61 |
| Q1 2021 | 2021-05-05 | -0.64 | -0.64 |
| Q4 2020 | 2021-02-23 | -1.02 | -1.02 |
| Q3 2020 | 2020-11-05 | -0.89 | 0.00 |
| Q2 2020 | 2020-08-06 | -1.15 | -1.15 |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-06-30 | Reiterated Rating | Stifel Nicolaus | Buy | $30.00 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray | Hold | $14.00 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray Cos. | Hold | $14.00 |
| 2016-06-08 | Reiterated Rating | Credit Suisse | Hold | |
| 2016-06-08 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-05-09 | Lower Price Target | WallachBeth Capital | Hold | $30.00 to $22.00 |
| 2016-05-08 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-04-18 | Initiated Coverage | Credit Suisse | Outperform | |
| 2016-04-13 | Reiterated Rating | Mizuho | Hold | |
| 2016-04-13 | Reiterated Rating | Janney Montgomery Scott | Buy | |
| 2016-04-13 | Downgrade | Credit Suisse | Outperform to Neutral | $32.00 to $14.00 |
| 2016-04-13 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $42.00 to $15.00 |
| 2016-04-12 | Reiterated Rating | Stifel Nicolaus | Buy | $30.00 |
| 2016-04-12 | Reiterated Rating | Piper Jaffray | Neutral | $18.00 |
| 2016-04-11 | Lower Price Target | Mizuho | Neutral | $21.00 to $15.00 |
| 2016-04-05 | Reiterated Rating | Piper Jaffray | Hold | $18.00 |
| 2016-04-04 | Initiated Coverage | Piper Jaffray | Neutral | $28.00 to $18.00 |
| 2016-03-28 | Boost Price Target | Leerink Swann | Outperform | $104.00 to $110.00 |
| 2016-02-29 | Lower Price Target | Mizuho | Neutral | $23.00 to $21.00 |
| 2016-02-26 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $42.00 |
| 2016-02-26 | Reiterated Rating | Stifel Nicolaus | Buy | $45.00 to $30.00 |
| 2016-02-22 | Lower Price Target | Goldman Sachs | $23.00 to $19.00 | |
| 2016-02-22 | Lower Price Target | Goldman Sachs Group Inc. | $23.00 to $19.00 | |
| 2016-01-25 | Lower Price Target | Mizuho | Neutral | $35.00 to $23.00 |
| 2016-01-20 | Initiated Coverage | Credit Suisse | Outperform | $32.00 |
| 2015-12-17 | Initiated Coverage | Janney Montgomery Scott | Buy | $50.00 |
| 2015-11-17 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $110.00 to $42.00 |
| 2015-11-17 | Downgrade | WallachBeth Capital | Buy to Hold | $135.00 to $30.00 |
| 2015-11-17 | Downgrade | Goldman Sachs | Buy to Neutral | $123.00 to $23.00 |
| 2015-11-16 | Reiterated Rating | Stifel Nicolaus | Buy | $140.00 to $45.00 |
| 2015-11-16 | Downgrade | Mizuho | Buy to Neutral | $114.00 to $35.00 |
| 2015-11-16 | Lower Price Target | Piper Jaffray | Neutral | $92.00 to $28.00 |
| 2015-11-06 | Boost Price Target | Mizuho | Buy | $103.00 to $114.00 |
| 2015-11-06 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $103.00 to $110.00 |
| 2015-09-10 | Boost Price Target | WallachBeth Capital | Buy | $115.00 to $134.00 |
| 2015-09-09 | Reiterated Rating | Piper Jaffray | Hold | $77.00 to $92.00 |
| 2015-09-08 | Reiterated Rating | Mizuho | Buy | $103.00 |
| 2015-09-02 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-08-10 | Reiterated Rating | JPMorgan Chase & Co. | Buy | $103.00 |
| 2015-08-07 | Reiterated Rating | Mizuho | Buy | $103.00 |
| 2015-07-20 | Lower Price Target | Piper Jaffray | Neutral | $100.00 to $77.00 |
| 2015-07-20 | Upgrade | Goldman Sachs | Buy to Conviction-Buy | $117.00 to $110.00 |
| 2015-07-02 | Reiterated Rating | Mizuho | Buy | |
| 2015-06-15 | Boost Price Target | WallachBeth Capital | Buy | $85.00 to $115.00 |
| 2015-06-01 | Reiterated Rating | JPMorgan Chase & Co. | Buy | |
| 2015-06-01 | Reiterated Rating | Mizuho | Buy | $100.00 to $103.00 |
| 2015-05-18 | Boost Price Target | Stifel Nicolaus | $125.00 | |
| 2015-05-16 | Reiterated Rating | Stifel Nicolaus | Buy | $90.00 to $125.00 |
| 2015-05-15 | Downgrade | Piper Jaffray | Overweight to Neutral | $100.00 |
| 2015-05-09 | Reiterated Rating | Goldman Sachs | Buy | |
| 2015-05-08 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $92.00 |
| 2015-04-13 | Upgrade | Goldman Sachs | Neutral to Buy | $68.00 to $117.00 |
| 2015-04-07 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | |
| 2015-02-26 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $92.00 |
| 2015-02-26 | Boost Price Target | Stifel Nicolaus | Buy | $75.00 to $90.00 |
| 2015-02-23 | Boost Price Target | Citigroup Inc. | Neutral | $60.00 to $85.00 |
| 2014-11-07 | Reiterated Rating | Citigroup Inc. | Neutral | $53.00 to $60.00 |
| 2014-11-07 | Reiterated Rating | Stifel Nicolaus | Buy | $50.00 to $75.00 |
| 2014-08-08 | Initiated Coverage | Leerink Swann | Outperform | $100.00 |
| 2014-06-05 | Upgrade | Stifel | Hold to Buy | $50 |
| 2014-06-05 | Upgrade | Stifel Nicolaus | Hold to Buy | $50.00 |
| 2014-06-04 | Lower Price Target | Goldman Sachs | Neutral | $85.00 to $50.00 |
| 2014-06-03 | Downgrade | Citigroup Inc. | Buy to Neutral | $109.00 to $53.00 |
| 2014-05-20 | Reiterated Rating | WallachBeth Capital | Buy | $85.00 |
| 2014-04-30 | Initiated | WallachBeth | Buy | $85 |
| 2014-04-30 | Initiated Coverage | WallachBeth Capital | Buy | $85.00 |
| 2014-03-24 | Initiated Coverage | Goldman Sachs | Neutral | $90.00 |
| 2014-03-05 | Boost Price Target | Credit Suisse | $78.00 to $100.00 | |
| 2014-02-28 | Boost Price Target | Leerink Swann | $104.00 to $110.00 | |
| 2014-01-28 | Boost Price Target | Mizuho | Buy | $90.00 to $100.00 |
| 2013-11-15 | Initiated Coverage | HC Wainwright | Neutral | $55.00 |
| 2013-09-27 | Reiterated Rating | Leerink Swann | Outperform | $88.00 |
| 2013-09-20 | Initiated Coverage | Citigroup Inc. | Buy | |
| 2013-06-25 | Initiated | Mizuho | Buy | $90 |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-06-30 | Reiterated Rating | Stifel Nicolaus | Buy | $30.00 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray | Hold | $14.00 |
| 2016-06-29 | Reiterated Rating | Piper Jaffray Cos. | Hold | $14.00 |
| 2016-06-08 | Reiterated Rating | Credit Suisse | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CLVS 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM